Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
Annovis Bio (NYSE: ANVS) announced its participation in the 13th Alzheimer's & Parkinson's Drug Development Summit in Boston, MA, from March 18-20, 2025. The company's Founder and CEO, Maria Maccecchini, Ph.D., will present Phase III buntanetap data and participate in a panel discussion on March 19.
The presentation at 3:30pm EST will focus on buntanetap's clinical trial results and advocate for a holistic approach to treating neurodegenerative diseases. At 4:30pm EST, Dr. Maccecchini will join a panel exploring opportunities in alpha-synuclein and future developments in Parkinson's drug development.
The company emphasizes the need to move beyond single-protein targeting approaches, highlighting their strategy of addressing multiple neurotoxic proteins in treating conditions like Alzheimer's and Parkinson's disease.
Annovis Bio (NYSE: ANVS) ha annunciato la sua partecipazione al 13° Summit sullo Sviluppo di Farmaci per l'Alzheimer e il Parkinson a Boston, MA, dal 18 al 20 marzo 2025. Il fondatore e CEO dell'azienda, Maria Maccecchini, Ph.D., presenterà i dati della Fase III di buntanetap e parteciperà a una discussione di panel il 19 marzo.
La presentazione, che avrà luogo alle 15:30 EST, si concentrerà sui risultati degli studi clinici di buntanetap e promuoverà un approccio olistico nel trattamento delle malattie neurodegenerative. Alle 16:30 EST, la Dr.ssa Maccecchini parteciperà a un panel che esplorerà le opportunità legate all'alfa-sinucleina e i futuri sviluppi nello sviluppo di farmaci per il Parkinson.
L'azienda sottolinea la necessità di andare oltre gli approcci che mirano a una singola proteina, evidenziando la propria strategia di affrontare più proteine neurotossiche nel trattamento di condizioni come l'Alzheimer e il Parkinson.
Annovis Bio (NYSE: ANVS) anunció su participación en la 13ª Cumbre sobre el Desarrollo de Medicamentos para el Alzheimer y el Parkinson en Boston, MA, del 18 al 20 de marzo de 2025. La fundadora y CEO de la empresa, Maria Maccecchini, Ph.D., presentará datos de la Fase III de buntanetap y participará en una discusión en panel el 19 de marzo.
La presentación, que tendrá lugar a las 15:30 EST, se centrará en los resultados de los ensayos clínicos de buntanetap y abogará por un enfoque holístico en el tratamiento de las enfermedades neurodegenerativas. A las 16:30 EST, la Dra. Maccecchini se unirá a un panel que explorará oportunidades en la alfa-sinucleína y futuros desarrollos en el desarrollo de medicamentos para el Parkinson.
La empresa enfatiza la necesidad de ir más allá de los enfoques de targeting de una sola proteína, destacando su estrategia de abordar múltiples proteínas neurotóxicas en el tratamiento de condiciones como el Alzheimer y el Parkinson.
Annovis Bio (NYSE: ANVS)는 2025년 3월 18일부터 20일까지 매사추세츠주 보스턴에서 열리는 제13회 알츠하이머 및 파킨슨 약물 개발 정상 회담에 참여한다고 발표했습니다. 회사의 창립자이자 CEO인 마리아 마체치니 박사가 3월 19일에 buntanetap의 3상 데이터를 발표하고 패널 토론에 참여할 예정입니다.
오후 3시 30분 EST에 진행되는 발표에서는 buntanetap의 임상 시험 결과에 초점을 맞추고 신경퇴행성 질환 치료에 대한 전체론적 접근을 옹호할 것입니다. 오후 4시 30분 EST에는 마체치니 박사가 알파-시뉴클레인 관련 기회와 파킨슨 약물 개발의 미래 발전을 탐구하는 패널에 참여할 것입니다.
회사는 단일 단백질 표적 접근 방식을 넘어설 필요성을 강조하며, 알츠하이머 및 파킨슨병과 같은 질환 치료에서 여러 신경독성 단백질을 다루는 전략을 강조합니다.
Annovis Bio (NYSE: ANVS) a annoncé sa participation au 13ème Sommet sur le Développement de Médicaments pour Alzheimer et Parkinson à Boston, MA, du 18 au 20 mars 2025. La fondatrice et PDG de l'entreprise, Maria Maccecchini, Ph.D., présentera les données de la Phase III de buntanetap et participera à une discussion en panel le 19 mars.
La présentation à 15h30 EST se concentrera sur les résultats des essais cliniques de buntanetap et plaidera pour une approche holistique dans le traitement des maladies neurodégénératives. À 16h30 EST, Dr. Maccecchini rejoindra un panel explorant les opportunités liées à l'alpha-synucléine et les développements futurs dans le développement de médicaments pour Parkinson.
L'entreprise souligne la nécessité de dépasser les approches ciblant une seule protéine, mettant en avant sa stratégie d'aborder plusieurs protéines neurotoxiques dans le traitement de conditions telles qu'Alzheimer et Parkinson.
Annovis Bio (NYSE: ANVS) gab seine Teilnahme am 13. Alzheimer- und Parkinson-Drug-Development-Gipfel in Boston, MA, vom 18. bis 20. März 2025 bekannt. Die Gründerin und CEO des Unternehmens, Maria Maccecchini, Ph.D., wird am 19. März Daten zur Phase III von buntanetap präsentieren und an einer Podiumsdiskussion teilnehmen.
Die Präsentation um 15:30 Uhr EST wird sich auf die klinischen Studienergebnisse von buntanetap konzentrieren und für einen ganzheitlichen Ansatz zur Behandlung neurodegenerativer Erkrankungen plädieren. Um 16:30 Uhr EST wird Dr. Maccecchini an einem Panel teilnehmen, das Chancen im Bereich Alpha-Synuclein und zukünftige Entwicklungen in der Parkinson-Forschung erörtert.
Das Unternehmen betont die Notwendigkeit, über Ansätze zur Zielsetzung einzelner Proteine hinauszugehen, und hebt seine Strategie hervor, mehrere neurotoxische Proteine bei der Behandlung von Erkrankungen wie Alzheimer und Parkinson anzugehen.
- Company's drug buntanetap has reached Phase III clinical trials
- Novel multi-target approach differentiates from competitors' single-protein targeting strategies
- None.
MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will participate at the 13th Alzheimer’s & Parkinson’s Drug Development Summit happening on March 18-20 in Boston, MA.
"This meeting represents an important opportunity to advance our understanding of the next-generation treatment for neurodegenerative diseases, which we have long argued are too complex for a narrow therapeutic approach. Research must shift to a more holistic solution, addressing multiple neurotoxic proteins and moving beyond the limited focus of targeting just one, which has hindered the progress in the field," says Maria Maccecchini, Ph.D., Founder and CEO of Annovis. “We will present the lessons learned from our AD and PD clinical trials, delve into buntanetap’s mechanism of targeting alpha-synuclein, and discuss ways to usher in a new era for Parkinson’s treatment.”
Annovis will give a presentation and participate in a panel discussion, both taking place on March 19:
Presentation: Highlighting Phase III Buntanetap Data & Embracing a More Holistic Approach to Neurodegenerative Disease Targeting
- Time: 3:30pm EST
- Presenter: Maria Maccecchini, Ph.D., Founder and CEO
Panel Discussion: Exploring Opportunities in Alpha-Synuclein & Beyond for More Transformative & Efficacious Therapies: What’s Coming Next in Parkinson’s Drug Development?
- Time: 4:30pm EST
- Participant from Annovis: Maria Maccecchini, Ph.D., Founder and CEO
The 13th Alzheimer’s & Parkinson’s Drug Development Summit is the only industry-focused, end-to-end meeting that provides comprehensive coverage from early discovery to late-stage development focused on deciphering the complexity of neurodegenerative diseases in pursuit of novel therapeutic targets.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
What will Annovis Bio (ANVS) present at the 2025 Alzheimer's & Parkinson's Summit?
How does Annovis Bio's buntanetap approach Parkinson's treatment differently?
When and where is Annovis Bio (ANVS) presenting at the Drug Development Summit?
What is the focus of Annovis Bio's panel discussion at the 2025 Summit?
